MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. (TBPH)

|||

Balance Sheets Overview

Current Ratio
1354.29%
Quick Ratio
1354.29%
Cash Ratio
714.31%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Short-term marketable securities
    • Other assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Unrecognized tax benefits
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
219,766
288,101
167,806
174,773
Short-term marketable securities
167,891
106,565
147,551
154,907
Receivables from collaborative arrangements
20,381
15,584
45,539
18,267
Receivables from milestones and royalty assets
-
-
50,000
-
Other prepaid and current assets
8,624
7,384
7,564
6,750
Total current assets
416,662
417,634
418,460
354,697
Long-term marketable securities
-
-
11,128
3,029
Property and equipment, net
5,169
5,539
5,895
6,257
Operating lease assets
21,926
23,001
24,371
25,450
Restricted cash
836
836
836
836
Other assets
25,177
25,303
24,880
25,191
Total assets
469,770
472,313
485,570
415,460
Accounts payable
652
1,100
2,568
2,213
Accrued personnel-related expenses
7,825
8,730
12,592
10,330
Accrued clinical and development expenses
2,395
2,396
3,373
5,842
Accrued general and administrative expenses
8,816
2,522
2,052
2,699
Operating lease liabilities
10,795
10,752
10,945
10,914
Income tax payable
-
5,287
5,287
4,074
Other accrued liabilities
283
988
1,485
1,335
Total current liabilities
30,766
31,775
38,302
37,407
Long-term operating lease liabilities
27,774
29,752
31,758
33,681
Future royalty payment contingency
32,795
32,795
32,795
32,213
Unrecognized tax benefits
88,486
87,153
85,679
79,165
Other long-term liabilities
244
244
313
313
Ordinary shares, 0.00001 par value per share 200,000 shares authorized 51,891 and 51,069 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively
1
1
1
1
Additional paid-in capital
1,160,238
1,155,215
1,156,288
1,153,299
Accumulated other comprehensive income (loss)
-76
-62
61
32
Accumulated deficit
-870,458
-864,560
-859,627
-920,651
Total shareholders' equity
289,705
290,594
296,723
232,681
Total liabilities and shareholders' equity
469,770
472,313
485,570
415,460
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$219,766K (-22.05%↓ Y/Y)Short-term marketablesecurities$167,891K (195.18%↑ Y/Y)Receivables fromcollaborative arrangements$20,381K (-7.02%↓ Y/Y)Other prepaid andcurrent assets$8,624K (54.80%↑ Y/Y)Total current assets$416,662K (13.75%↑ Y/Y)Other assets$25,177K (-2.30%↓ Y/Y)Operating lease assets$21,926K (-17.24%↓ Y/Y)Property and equipment,net$5,169K (-22.17%↓ Y/Y)Restricted cash$836K (0.00%↑ Y/Y)Total assets$469,770K (10.27%↑ Y/Y)Total liabilities andshareholders' equity$469,770K (10.27%↑ Y/Y)Total shareholders'equity$289,705K (28.84%↑ Y/Y)Unrecognized tax benefits$88,486K (13.73%↑ Y/Y)Future royalty paymentcontingency$32,795K (3.65%↑ Y/Y)Total currentliabilities$30,766K (-43.69%↓ Y/Y)Long-term operating leaseliabilities$27,774K (-21.90%↓ Y/Y)Other long-termliabilities$244K (-84.24%↓ Y/Y)Accumulated deficit-$870,458K (5.82%↑ Y/Y)Accumulated othercomprehensive income (loss)-$76K (-660.00%↓ Y/Y)Additional paid-in capital$1,160,238K (0.97%↑ Y/Y)Operating leaseliabilities$10,795K (-0.93%↓ Y/Y)Accrued general andadministrative expenses$8,816K (258.52%↑ Y/Y)Accruedpersonnel-related expenses$7,825K (7.80%↑ Y/Y)Accrued clinical anddevelopment expenses$2,395K (-36.69%↓ Y/Y)Accounts payable$652K (-61.07%↓ Y/Y)Other accruedliabilities$283K (-84.83%↓ Y/Y)Ordinary shares, 0.00001par value per share...$1K (0.00%↑ Y/Y)